O	0	9	Favorable
O	10	17	effects
O	18	20	of
B-intervention	21	24	low
I-intervention	24	25	-
I-intervention	25	28	fat
I-intervention	29	32	and
I-intervention	33	36	low
I-intervention	36	37	-
I-intervention	37	49	carbohydrate
I-intervention	50	57	dietary
I-intervention	58	66	patterns
O	67	69	on
O	70	75	serum
O	76	82	leptin
O	82	83	,
O	84	87	but
O	88	91	not
O	92	103	adiponectin
O	103	104	,
O	105	110	among
O	111	121	overweight
O	122	125	and
O	126	131	obese
O	132	145	premenopausal
O	146	151	women
O	151	152	:
O	153	154	a
O	155	165	randomized
O	166	171	trial
O	171	172	.

O	173	176	The
O	177	181	most
O	182	191	effective
O	192	199	dietary
O	200	207	pattern
O	208	211	for
O	212	218	breast
O	219	225	cancer
O	226	236	prevention
O	237	240	has
O	241	245	been
O	246	253	greatly
O	254	261	debated
O	262	264	in
O	265	271	recent
O	272	277	years
O	277	278	.

O	279	286	Studies
O	287	291	have
O	292	300	examined
O	301	312	hypocaloric
O	313	318	diets
O	318	319	,
O	320	324	with
O	325	335	particular
O	336	344	emphasis
O	345	347	on
O	348	361	macronutrient
O	362	373	composition
O	373	374	,
O	375	383	yielding
O	384	396	inconclusive
O	397	401	data
O	401	402	.

O	403	406	The
O	407	416	objective
O	417	419	of
O	420	424	this
O	425	430	study
O	431	434	was
O	435	437	to
O	438	445	examine
O	446	449	the
O	450	457	effects
O	458	460	of
O	461	468	calorie
O	468	469	-
O	469	479	restricted
O	480	483	low
O	483	484	-
O	484	487	fat
O	488	491	and
O	492	495	low
O	495	496	-
O	496	508	carbohydrate
O	509	514	diets
O	515	516	(
O	516	519	LFD
O	520	523	and
O	524	527	LCD
O	527	528	,
O	529	541	respectively
O	541	542	)
O	543	545	on
O	546	557	circulating
O	558	568	adipokines
O	569	574	among
O	575	585	overweight
O	586	589	and
O	590	595	obese
O	596	609	premenopausal
O	610	615	women
O	615	616	.

B-total-participants	617	624	Seventy
I-total-participants	624	625	-
I-total-participants	625	629	nine
B-eligibility	630	640	overweight
I-eligibility	641	644	and
I-eligibility	645	650	obese
I-eligibility	651	664	premenopausal
I-eligibility	665	670	women
O	671	675	were
O	676	686	randomized
O	687	689	to
O	690	696	either
O	697	700	LFD
O	701	703	or
O	704	707	LCD
O	707	708	,
O	709	713	with
O	714	723	increased
O	724	732	physical
O	733	741	activity
O	741	742	,
O	743	746	for
O	747	749	52
O	750	755	weeks
O	755	756	.

B-outcome	757	762	Serum
I-outcome	763	774	adiponectin
O	774	775	,
B-outcome	776	782	leptin
O	783	786	and
O	787	790	the
B-outcome	791	802	adiponectin
I-outcome	802	803	-
I-outcome	803	805	to
I-outcome	805	806	-
I-outcome	806	812	leptin
I-outcome	813	818	ratio
I-outcome	819	820	(
I-outcome	820	821	A
I-outcome	821	822	/
I-outcome	822	823	L
I-outcome	823	824	)
O	825	829	were
O	830	838	measured
O	839	841	at
O	842	850	baseline
O	850	851	,
O	852	855	and
O	856	858	at
O	859	864	weeks
O	865	867	34
O	868	871	and
O	872	874	52
O	875	877	to
O	878	884	assess
O	885	897	intervention
O	898	905	effects
O	905	906	.

O	907	912	While
O	913	918	there
O	919	923	were
O	924	926	no
O	927	938	significant
O	939	946	changes
O	947	949	in
O	950	955	serum
O	956	967	adiponectin
O	968	982	concentrations
O	983	992	following
O	993	996	the
O	997	1000	LCD
O	1001	1004	and
O	1005	1008	LFD
O	1009	1022	interventions
O	1022	1023	,
B-outcome	1024	1030	leptin
I-outcome	1031	1045	concentrations
O	1046	1059	significantly
O	1060	1069	decreased
O	1070	1072	by
O	1073	1077	week
O	1078	1080	34
O	1081	1083	of
O	1084	1087	the
O	1088	1100	intervention
O	1101	1107	period
O	1108	1109	(
O	1109	1112	LCD
O	1112	1113	:
B-iv-cont-mean	1114	1116	35
I-iv-cont-mean	1116	1117	.
I-iv-cont-mean	1117	1118	3
I-iv-cont-mean	1118	1119	%
O	1119	1120	,
O	1121	1122	P
O	1123	1124	=
O	1125	1126	0
O	1126	1127	.
O	1127	1130	004
O	1130	1131	;
O	1132	1135	LFD
O	1135	1136	:
B-iv-cont-mean	1137	1139	30
I-iv-cont-mean	1139	1140	.
I-iv-cont-mean	1140	1141	0
I-iv-cont-mean	1141	1142	%
O	1142	1143	,
O	1144	1145	P
O	1146	1147	=
O	1148	1149	0
O	1149	1150	.
O	1150	1152	01
O	1152	1153	)
O	1153	1154	,
O	1155	1159	with
O	1160	1162	no
O	1163	1173	difference
O	1174	1176	by
O	1177	1189	intervention
O	1190	1193	arm
O	1193	1194	.

O	1195	1197	At
O	1198	1202	week
O	1203	1205	52
O	1205	1206	,
O	1207	1212	these
O	1213	1223	reductions
O	1224	1228	were
O	1229	1242	statistically
O	1243	1246	non
O	1246	1247	-
O	1247	1258	significant
O	1258	1259	,
O	1260	1270	indicating
O	1271	1272	a
O	1273	1279	return
O	1280	1282	to
O	1283	1291	baseline
O	1292	1298	levels
O	1299	1301	by
O	1302	1305	the
O	1306	1309	end
O	1310	1312	of
O	1313	1316	the
O	1317	1329	intervention
O	1329	1330	.

O	1331	1336	While
O	1337	1342	there
O	1343	1347	were
O	1348	1351	non
O	1351	1352	-
O	1352	1363	significant
O	1364	1373	increases
O	1374	1376	in
O	1377	1380	the
B-outcome	1381	1382	A
I-outcome	1382	1383	/
I-outcome	1383	1384	L
I-outcome	1385	1390	ratio
O	1391	1400	following
O	1401	1404	the
O	1405	1408	LCD
O	1409	1412	and
O	1413	1416	LFD
O	1417	1429	intervention
O	1430	1434	arms
O	1434	1435	,
O	1436	1439	the
O	1440	1447	overall
O	1448	1453	trend
O	1453	1454	,
O	1455	1461	across
O	1462	1468	groups
O	1468	1469	,
O	1470	1473	was
O	1474	1484	marginally
O	1485	1496	significant
O	1497	1498	(
O	1498	1499	P
O	1500	1501	=
O	1502	1503	0
O	1503	1504	.
O	1504	1506	05
O	1506	1507	)
O	1508	1512	with
O	1513	1522	increases
O	1523	1525	of
B-iv-cont-mean	1526	1528	16
I-iv-cont-mean	1528	1529	.
I-iv-cont-mean	1529	1530	2
I-iv-cont-mean	1530	1531	%
O	1532	1535	and
B-iv-cont-mean	1536	1538	35
I-iv-cont-mean	1538	1539	.
I-iv-cont-mean	1539	1540	1
I-iv-cont-mean	1540	1541	%
B-outcome	1542	1544	at
I-outcome	1545	1550	weeks
I-outcome	1551	1553	34
I-outcome	1554	1557	and
I-outcome	1558	1560	52
O	1560	1561	,
O	1562	1574	respectively
O	1574	1575	.

O	1576	1581	These
O	1582	1590	findings
O	1591	1598	suggest
O	1599	1603	that
O	1604	1611	caloric
O	1611	1612	-
O	1612	1622	restricted
O	1623	1626	LCD
O	1627	1630	and
O	1631	1634	LFD
O	1635	1642	dietary
O	1643	1651	patterns
O	1652	1661	favorably
O	1662	1668	modify
O	1669	1675	leptin
O	1676	1679	and
O	1680	1688	possibly
O	1689	1692	the
O	1693	1694	A
O	1694	1695	/
O	1695	1696	L
O	1697	1702	ratio
O	1702	1703	,
O	1704	1707	and
O	1708	1712	lend
O	1713	1720	support
O	1721	1723	to
O	1724	1727	the
O	1728	1738	hypothesis
O	1739	1743	that
O	1744	1749	these
O	1750	1763	interventions
O	1764	1767	may
O	1768	1770	be
O	1771	1780	effective
O	1781	1784	for
O	1785	1792	obesity
O	1792	1793	-
O	1793	1800	related
O	1801	1807	breast
O	1808	1814	cancer
O	1815	1825	prevention
O	1826	1833	through
O	1834	1839	their
O	1840	1847	effects
O	1848	1850	on
O	1851	1861	biomarkers
O	1862	1870	involved
O	1871	1873	in
O	1874	1883	metabolic
O	1884	1892	pathways
O	1892	1893	.

O	1895	1906	NCT01559194
O	1906	1907	.
